Episode Details

It’s a holiday week. We just wrapped three intense days at the American College of Lifestyle Medicine conference - 2,200 practitioners, researchers, and changemakers gathering around a board certification that could eliminate 60-70% of established chronic disease costs. The crowd was significantly larger than last year, which tells you something about momentum. But as always with healthcare transformation, the picture is complicated. We thought this video would be a fun during and after from the American College of Lifestyle Medicine Conference.

The Core Tension: Healthcare Can’t See Food (Unless It’s a Drug)

Our conversation with Dr. Sachin Jain crystallized something we’ve been wrestling with: it’s incredibly difficult to get our minds out of the economics of one industry versus the other and think about it as a system design challenge of chronic disease.

Healthcare wants to keep people sick - that’s how the engine runs. Food, on the other hand, is neutral. Food just wants to keep people happy and buying product. They don’t have a vested interest in whether you’re sick or healthy. If you could feed somebody the same calories in a much healthier configuration for the same amount of money, food wouldn’t care. They’d just redesign to match demand.

That’s why we increasingly believe food needs to lean into healthcare, not the other way around. There’s less friction. Food has less skin in the game of staying entrenched in the current system. Healthcare is reimbursed, it’s regulated - food’s not. You can change your diet tomorrow. Nobody’s going to step in and say that’s not allowed.

The Practitioner’s Dilemma: When the CEO Won’t Expand the Program

There was a revealing moment during Dr. Joseph’s keynote—the cardiologist who launched the lifestyle medicine program at St. Francis in Tulsa. Someone from the audience asked: “How did you get your CEO to buy into this?”

That question is endemic of what’s happening. The majority of lifestyle medicine assets today are those clinicians. About half are independent practitioners who could potentially deploy differently. The other half? They’re employed by incumbent legacy health systems operating under the current healthcare finance model. Systems that see lifestyle medicine like primary care—it doesn’t make money. It’s much better to do more joints, have more beds, deliver more acute care.

There’s still political discourse about how that program fits in. It was the perfect epitome of what we’re up against: over 2,000 people came together around something so simple in it’s delivery that could take 60-70% of chronic disease costs out of the system. Yet we still monetize sickness to keep the engine running.

Five Forces Converging (Finally)

Despite the friction, we see five powerful forces all moving toward transformation:

* The sickest patients on GLP-1s now generate less revenue for hospitals - the economic model cracking

* Patients without chronic disease are taking control - they’re avoiding the system entirely

* Geopolitical pressure - when you look at US and China, both spend heavily on healthcare and military. When GLP-1s go off patent in China in 2026, they can spend more on defense. The US government has interest in making Americans healthy from a national security standpoint

* Enhanced benefits and HSA funding potential - we posed the question of what happens if HSAs were well-funded, if there was more cash in consumers’ hands. That was a market force people hadn’t considered

* Next-generation GLP-1s and innovation in lifestyle medicine - from frontline practitioners creating new business models all the way to Washington

Lily Goes Direct: Getting Closer to the Signal

Since ACLM, Eli Lilly announced they’re going direct to corporations with GLP-1s